sacituzumab govitecan,Pembrolizumab,Avelumab,Zimberelimab,Domvanalimab
Gilead Sciences,Merck,Pfizer,Arcus Biosciences,Otsuka
['muc ,(-much)', 'vedo', ' ave ', 'pembro', ' vedo', ' sg ', ' cis ', 'trophy,u-01', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', ' gem ', 'nivo', 'bladder']
trophy-u-01 cohort 2: daniel p. petrylak, md, -orr was 32%
-median pfs was 5.6 mo
-median os was 13.5 mo #gu23 #medtwitter #bladdercancer 
On the road!
Pursuing to improve global health through sharing knowledge, cancer prevention, and care.  
Medical oncologist @AnkaraUni